BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24372512)

  • 1. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
    Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
    Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
    Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
    Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
    Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
    Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
    Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
    Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
    Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
    Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study.
    Mullier F; Daliphard S; Garand R; Dekeyser M; Cornet Y; Luquet I; Talmant P; Richebourg S; Jamar M; Dogné JM; Chatelain C; Michaux L; Chatelain B
    Ann Hematol; 2012 Feb; 91(2):203-13. PubMed ID: 21744002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
    Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
    Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Report of ten cases of hematologic malignancies with idic(20q-) and literature review].
    Han YS; Xue YQ; Li TY; Zhang J; Chen SN; Pan JL; Wu YF; Wang Y; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):17-20. PubMed ID: 21429395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and cytogenetic features of 29 cases of myelodysplastic syndrome associated with del(20q)].
    Qin S; Liu SH; Bo LJ; Liu XP; Li CW; Dai Y; He GS; Shao ZH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):171-2. PubMed ID: 15079804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission.
    Sun J; Yin CC; Cui W; Chen SS; Medeiros LJ; Lu G
    Am J Clin Pathol; 2011 Mar; 135(3):391-7. PubMed ID: 21350093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation.
    Gupta R; Soupir CP; Johari V; Hasserjian RP
    Br J Haematol; 2007 Oct; 139(2):265-8. PubMed ID: 17764468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.